[Problem] To provide a canine madness vaccine which is higly safe, effective and inexpensive.[Solution] Provided are: a mutant canine madness virus (e.g., strain ERA-N273/394-G333 shown in fig. 2) which has at least the following mutations in a structural protein of a canine madness virus, i.e., the mutation of the amino acid reside at position-273 in N protein into an amino acid residue other than phenylalanine, the mutations of the amino acid reside at position-394 in N protein into an amino acid residue other than tyrosine, and the mutation of the amino acid residue at position-333 in G protein into an amino acid residue other than arginine or lysine a canine madness vaccine preparation containing the mutant canine madness virus and others. The introduction of the mutation of the amino acid residue at position-333 in G protein induces the attenuation of the virulence of a canine madness virus, and the introduction of the mutations of the amino acid residues at position-273 and position-394 in N protein induces the improvement in immunogenicity and safety of the canine madness virus. In addition, the introduction of the mutations of the amino acid residues at position-273 and position-394 in N protein enables the prevention of the increase in the virulence of the canine madness virus even when the mutation of the amino acid residue at position-194 in G protein into lysine occurs and, as a result, the possibility of the occurrence of reversion of pathogenicity of the canine madness virus caused by mutation can be reduced and the safety of the canine madness virus can be further improved.[Problème] Produire un vaccin contre la rage qui est très sûr, efficace et économique.[Solution] La présente invention concerne : un virus de la rage mutant (par exemple, la souche ERA-N273/394-G333 représentée sur la figure 2) qui a au moins les mutations suivantes dans une protéine structurale dun virus de la rage, cest-à-dire, la mutation de lacide aminé résidant à la position 27
